Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days.
- This filing includes Item 3.01, an item that often signal trouble.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days
- Immediate delisting not triggered: shares continue trading on Nasdaq Capital Market
- Compliance deadline May 18, 2027, requiring at least $1.00 bid for 10 consecutive business days
- Potential second 180-day cure period, contingent on meeting other Nasdaq listing standards
- Reverse stock split remains a possible remedy, creating dilution and trading-volatility risk for shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.